---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-25-000064"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:41:50.134056+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Autolus reports Q2 AUCATZYL revenue $20.9M; EU/UK approvals secured but Germany launch on hold

## Summary
- Net product revenue $20.9M in Q2, $29.9M H1 2025; 46 U.S. centers activated, >90% medical lives covered.
- UK MHRA (Apr 25) and EC (Jul 17) conditional approvals granted for AUCATZYL in r/r B-ALL.
- NICE preliminary ACD recommended against funding; EU launch paused, no sales expected in 2025-2026.
- Cash $454.3M (Jun 30 vs $588.0M Dec 31); net loss $47.9M (Q2 2025) vs $58.3M (Q2 2024).
- Pipeline: obe-cel Phase 2 LN trial and Phase 1 MS trial first patient dosing by year-end 2025.

## SEC filing metadata
- accession: 0001730463-25-000064
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000064/0001730463-25-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000064/autl-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-25-000064
- JSON: https://secwatch.observer/filing/0001730463-25-000064.json
- Plain text: https://secwatch.observer/filing/0001730463-25-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.